|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrate that low expression of miR-15a is associated with poor prognosis of PDAC patients. miR-15a expression is reduced in PDAC while closely related miR-16 expression remains relatively unchanged. miR-15a suppresses several important targets such as Wee1, Chk1, Yap-1, and BMI-1, causing cell cycle arrest and inhibiting cell proliferation.
|
31846800 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Additionally, CBX4 promotes proliferation and metastasis via regulating the expression of BMI-1 which is a significant regulator of proliferation and migration in lung cancer cells.
|
31724308 |
2020 |
|
Malignant neoplasm of lung
|
0.070 |
Biomarker
|
disease |
BEFREE |
CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer.
|
31724308 |
2020 |
|
Carcinoma of lung
|
0.070 |
Biomarker
|
disease |
BEFREE |
CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer.
|
31724308 |
2020 |
|
Primary malignant neoplasm of lung
|
0.070 |
Biomarker
|
disease |
BEFREE |
CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer.
|
31724308 |
2020 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
The overexpression of ANGPTL4 induced GSC enrichment that was characterized by polycomb complex protein BMI-1 and SRY (sex determining region Y)-box 2 (SOX2) expression, resulting in TMZ resistance in GBM.
|
31717924 |
2019 |
|
Glioblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The overexpression of ANGPTL4 induced GSC enrichment that was characterized by polycomb complex protein BMI-1 and SRY (sex determining region Y)-box 2 (SOX2) expression, resulting in TMZ resistance in GBM.
|
31717924 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.030 |
Biomarker
|
disease |
BEFREE |
BMI-1 was verified as a direct target of miR-15 in BC using Luciferase reporter assay.
|
31696468 |
2019 |
|
Bladder Neoplasm
|
0.030 |
Biomarker
|
disease |
BEFREE |
BMI-1 was verified as a direct target of miR-15 in BC using Luciferase reporter assay.
|
31696468 |
2019 |
|
Carcinoma of bladder
|
0.030 |
Biomarker
|
disease |
BEFREE |
BMI-1 was verified as a direct target of miR-15 in BC using Luciferase reporter assay.
|
31696468 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Here, we investigated the impact of PTC-209, a small-molecule Bmi-1 inhibitor, on human cancer cell viability alone and in combination with anticancer drugs, namely, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, and Frondoside-A and its impact on cellular migration and colony growth <i>in vitro</i> and on tumor growth <i>in ovo</i>.
|
31695609 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The consequent upregulation of nuclear FoxO3a and its binding to the Bmi-1 promoter, may account for the self-renewal activity of breast cancer stem-like cells and their growth in a xenograft mouse model.
|
31672029 |
2020 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The consequent upregulation of nuclear FoxO3a and its binding to the Bmi-1 promoter, may account for the self-renewal activity of breast cancer stem-like cells and their growth in a xenograft mouse model.
|
31672029 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, a biocompatible nanocarrier was designed in the study to deliver a chemotherapeutical agent CDDP and Bmi-1 siRNA to kill cancer cells and silence drug resistance related gene simultaneously.
|
31669557 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bmi-1 is also an oncogene promoting malignance of tumor and an anti-cancer target in many studies.
|
31669557 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, a biocompatible nanocarrier was designed in the study to deliver a chemotherapeutical agent CDDP and Bmi-1 siRNA to kill cancer cells and silence drug resistance related gene simultaneously.
|
31669557 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bmi-1 is a gene related to malignant transformation in hepatocellular carcinoma (HCC).
|
31669557 |
2019 |
|
Malignant transformation
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Bmi-1 is a gene related to malignant transformation in hepatocellular carcinoma (HCC).
|
31669557 |
2019 |
|
Adult Liver Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The liver cancer cells developed the ability to tolerate CDDP treatment with the elevation of Bmi-1.
|
31669557 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The liver cancer cells developed the ability to tolerate CDDP treatment with the elevation of Bmi-1.
|
31669557 |
2019 |
|
Malignant neoplasm of liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
The liver cancer cells developed the ability to tolerate CDDP treatment with the elevation of Bmi-1.
|
31669557 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BMI-1, a critical regulator of self-renewal in the maintenance of CICs, is identified as a potential target for colorectal cancer therapy.
|
31640758 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
Biomarker
|
disease |
BEFREE |
BMI-1, a critical regulator of self-renewal in the maintenance of CICs, is identified as a potential target for colorectal cancer therapy.
|
31640758 |
2019 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
Furthermore, Bmi-1 and Cyclin D2 were found to be positively regulated by USP22, which may have mediated the tumorigenic effects of USP22 in human colon cancer.
|
31612065 |
2019 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Furthermore, Bmi-1 and Cyclin D2 were found to be positively regulated by USP22, which may have mediated the tumorigenic effects of USP22 in human colon cancer.
|
31612065 |
2019 |